<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318587</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19090098</org_study_id>
    <nct_id>NCT04318587</nct_id>
  </id_info>
  <brief_title>Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation</brief_title>
  <official_title>Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pablo Sanchez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Allosure to identify and quantify circulating donor-derived cell-free DNA to
      quantitate allograft injury in the early post-transplant period and determine its
      relationship to allograft failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single Center Prospective Cohort Study on De-Novo Lung Transplant recipients. AlloSure will
      be drawn as part of routine blood draws and sent to CareDx for analysis of dd-cfDNA. All data
      will be collected and stored in the hospital EMR, this will be examined with the AlloSure
      results to correlate outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Correlate donor DNA in blood samples to episodes of Acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry
From this correlation we hope to be able to develop a miniMally invasive test ( blood sample) that can predict or correlate acute and or chronic rejection</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>24 hours post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>48 hours post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>72 hours post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>3 months post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>9 months post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary graft dysfunction/allograft rejection</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>incidence of dysfunction/rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>pre-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>24 hours post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>48 hours post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>72 hours post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>1 week post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>2 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>3 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>4 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>5 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>6 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>7 weeks post-transplant</time_frame>
    <description>results of Allosure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>8 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>9 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>10 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>11 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>12 weeks post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>results of Allosure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>7 months post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>8 months post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>9 months post-transplant</time_frame>
    <description>results of Allosure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>10 months post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>11 months post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allosure dd-cDNA</measure>
    <time_frame>12 months post-transplant</time_frame>
    <description>amount of dd-cDNA in recipient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of AlloSure in the predictive and prognostic value of diagnosing CLAD/allograft failure/premature death</measure>
    <time_frame>From date of transplant until the date of graft failure or date of death from any cause, whichever came first, assessed up to 60 months.</time_frame>
    <description>incidence of biopsy, PFT, and AlloSure results that are correlated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Transplant Failure and Rejection</condition>
  <arm_group>
    <arm_group_label>Allosure Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be in arm one and will have AlloSure blood draws at multiple time points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Allosure</intervention_name>
    <description>Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.</description>
    <arm_group_label>Allosure Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Male or Female, aged 18 years or above.

          -  Denovo lung transplant recipient

          -  Ability to understand written and spoken English

        Exclusion Criteria:

          -  Previous transplant or multi-organ transplant

          -  Unable to have blood draw for medical reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Program Director Residency Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo Sanchez, MD</last_name>
    <phone>412-648-6315</phone>
    <email>sanchezpg@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi Ryssel, MPH</last_name>
    <phone>412-647-7025</phone>
    <email>agostinonr@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Sanchez, MD</last_name>
      <phone>412-648-6315</phone>
      <email>sanchezpg@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Pablo Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Pablo Sanchez</investigator_full_name>
    <investigator_title>Vice Chair, Benign Lung Diseases Surgical Director, Lung Transplant and ECMO, Director, Lung Transplant Research and ELVP Program</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the article, after de-identification (text, tables, figures, and appendices)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

